Skip to main content
. Author manuscript; available in PMC: 2022 Apr 15.
Published in final edited form as: AAPS PharmSciTech. 2021 Apr 15;22(4):136. doi: 10.1208/s12249-021-02001-1

Table V.

Surfactant activity of commercial Survanta® and l-leucine containing Survanta EEG powder (values are mean (standard deviation), n=3).

Formulation Surface age
(s)
Final Surface
Tension
(mN/m)
Surface tension
reduction rate
(mN/m/s)
Survanta® 59.0 (13.1) 29.9 (5.5) 0.73 (0.16)
L-leucine-Survanta EEG 65.6 (1.3) 33.0 (1.5) 0.58 (0.07)